14.1.2008
Richard N. Fogoros, M.D. sanoo aika kovia nettikirjoittelussaan.
Poimintoja:
Lainaa:
As I commented on December 17, "..... the fact that the endpoints of the trial were apparently changed after the study was concluded, followed by the fact that apparently now they have been changed back, is strong evidence that the data is being vigorously manipulated. And if the data's being manipulated, one could naturally conclude that the data, analyzed as originally intended, is unfavorable to Vytorin. Which, just as naturally, raises the final question: Are the results "merely negative" (that is, Vytorin appears no more beneficial than simvatatin alone), or are they "really negative" (that is, Vytorin is substantially worse than simvastatin alone)?" Today's release of data begins to answer this question.
Lainaa:
However, the data released today showed no benefit for Vytorin over simvastatin. In fact, while the results were not statistically significant, patients on Vytorin had more plaque growth than patients taking only simvastatin. (The arterial wall thickness increased by 0.0111 mm for Vytorin, but only by 0.0058 mm for simvastatin alone - a ratio of nearly 2:1.)
30.3.2008
No Good News For Vytorin or ZetiaLainaa:
Today the official results of the ENHANCE trial were finally presented, simultaneously, at the American College of Cardiology Scientific Sessions in Chicago, and in print in the New England Journal of Medicine. While some were half expecting the sponsors to pull a rabbit out of the hat at the last minute, and show that Vytorin actually does provide some measurable benefit to patients with high cholesterol levels, that did not happen.
There were no surprises of note.
As I have previously described, despite the signific.........
Lainaa:
Indeed, the fact that carotid artery wall thickness actually increased more in patients taking Vytorin than those taking simvastatin alone (though the difference was not statistically significant) raises at least the possibility that Vytorin and Zetia ought to be avoided unless they are really necessary to achieve target cholesterol levels.
Niin juu.... suomessahan juuri näistä lääkkeistä ei tietenkään ole kuultukaan, suomea vartenhan tehdään ihan eri lääkkeet... täällä sama
nkaltaista ja kallista placeboa syötetään uskotellen potilaille että...
Loppukevennys noista ensmmäisen lopusta:
Lainaa:
The biggest widespread harm caused by Vytorin, judging from the data available so far, is probably to pocketbooks - Vytorin is far, far more expensive than simvastatin alone, which is now available as a cheap generic drug. And while it's probably not a "harm," those commercials comparing your Uncle Harry to a plate of pancakes and eggs are among the most annoying I've seen. We can only hope that, thirty seconds after releasing their press statements today, the sponsors of ENHANCE canceled all those commercials. In which case the ENHANCE trial will have yielded positive results after all.
Kirjaudu sisään
UKK
Etsi
